Elena Battistello

Analyst, Novartis Venture Fund at Novartis

Postdoctoral Fellow
2020 - 2023
Department of Pathology, NYU School of Medicine • Directed research projects aimed at dissecting the epigenetic regulation of T cell exhaustion to improve T-cell therapies efficacy in hematological tumors (Battistello*, Hixon*, Comstock* et al, Molecular Cell, 2023) • Designed a protocol to increase the fitness of CAR-T cells through epigenomic rewiring (patent filed) • Used single-cell transcriptomic and epigenomic tools to dissect the contribution of the tumor microenvironment to CAR-T cell efficacy • Investigated the epigenome of T cell lymphoma clinical samples to identify novel therapeutic targets • Contributed to the design and implementation of clinical studies at NYU Langone Health • Coordinated a team of two technicians and one graduate student • Raised funding through the Swiss National Science Foundation and the Lymphoma Research Foundation ($185,700 total)

Postdoctoral Fellow
2019 - 2019
• Led research activities targeting therapy resistance in lymphoma • Developed a screening pipeline currently used for drug discovery
PhD Student
2015 - 2019
Swiss Institute for Experimental Cancer Research, EPFL Department of Computational Biology, University of Lausanne • Directed translational research projects aimed at identifying novel therapeutic targets and immunotherapy approaches in hematological tumors (Dheilly*, Battistello* et al., Cancer Cell, 2020; Battistello et al., Blood, 2018). • Designed a drug discovery platform to target the activity of a specific protease in Diffuse Large B cell Lymphoma • Supervised undergraduate students and served as teaching assistant at Cancer Biology courses
Internship
2015 - 2015